ArticleCancer science2013
Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma.
Article in Cancer science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.Cancer research · 2014Pooled it
- Population Pharmacokinetics and Exposure-Response Analyses to Support Cofetuzumab Pelidotin (ABBV-647) Dose Optimization in Non-Small Cell Lung Cancer Patients.Clinical pharmacology and therapeutics · 2026Article
- Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer.Oncogene · 2024Review
- PTK7: an underestimated contributor to human cancer.Frontiers in oncology · 2024Review
- MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.Molecular cancer therapeutics · 2023Article
- Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling.International journal of molecular sciences · 2023Article
- Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma.International journal of molecular sciences · 2022Article
- Article
- PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells.International journal of molecular sciences · 2022Article
- Whole-Exome Sequencing Identifies a Novel Germline Variant inInternational journal of molecular sciences · 2022Article
- A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.Frontiers in pharmacology · 2022Review
- First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Importance of Nano Medicine and New Drug Therapies for Cancer.Advanced pharmaceutical bulletin · 2021Review
- PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.Frontiers in immunology · 2021Article
- PTK7 promotes the malignant properties of cancer stem-like cells in esophageal squamous cell lines.Human cell · 2020Article
- PTK-7 Expression in Gastric Cancer: A Prognostic DeterminantBalkan medical journal · 2020Article
- Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.Cancer medicine · 2019Article
- Nanoparticle Activation Methods in Cancer Treatment.Biomolecules · 2019Review
- Biphasic regulation of tumorigenesis by PTK7 expression level in esophageal squamous cell carcinoma.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is a common subtype of esophageal cancer that is particularly prevalent in East Asian countries. Our previous expression profile analysis showed that the gene encoding protein tyrosine kinase 7 (PTK7) is upregulated in ESCC tissues. Here, we aimed to validate PTK7 as a prognostic factor and a candidate target for molecular treatment of ESCC. Both RT-PCR and Western blot analysis of tissues from ESCC patients revealed that PTK7 was significantly upregulated in tumor tissue samples of ESCC. Immunohistochemical staining of PTK7 showed that increased expression of PTK7 was inversely correlated with overall survival (P = 0.021). In vitro knockdown of PTK7 inhibited proliferation, survival, wound healing, and invasion of ESCC cells. In addition, PTK7 knockdown decreased phosphorylation of Akt, Erk, and focal adhesion kinase (FAK), important determinants of cell proliferation, survival, and migration. Therefore, our findings suggest that PTK7 has potential as a prognostic marker for ESCC and might also be a candidate for targeted therapy in the treatment of ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.